Introduction of PEXOTRA
500MG INJECTION:

PEXOTRA 500MG INJECTION contains
Pemetrexed which belongs to the group of medicines called Anticancer agents. It
is used to manage advanced stages of non-small cell lung cancer (NSCLC). It can
be used as a management option to control cancer progression in patients who
have failed to respond adequately to conventional therapies.

PEXOTRA 500MG INJECTION is also used to manage malignant cancer of
pleural membrane (a protective layer surrounding the lungs), called as pleural
mesothelioma. It is mostly used in combination with other anti-cancer medicines
(such as cisplatin, carboplatin) to achieve better results.

Before receiving PEXOTRA 500MG INJECTION inform your doctor if you
have any lung, liver, kidney or heart problems or a previous history of the
same. You must also inform your doctor if you have fluid accumulation in the
lungs or recently received or planning to receive any radiation therapy or
vaccination in the upcoming days as a precaution.

PEXOTRA 500MG INJECTION is not recommended for use in pregnant or
breastfeeding women and in children aged below 18 years. Men and women
receiving PEXOTRA 500MG INJECTION must use a suitable contraceptive method to
avoid pregnancy while undergoing therapy with PEXOTRA 500MG INJECTION and for
until 6 months after stopping the therapy.

The most common side effects of receiving PEXOTRA 500MG INJECTION
are increased infections, sore throat, nausea, vomiting, stomach pain,
dizziness, tiredness, weight loss, changes in taste, skin rash, hair loss and
mouth ulcers. Contact your doctor if any of these side effect worsens.

Uses of PEXOTRA
500MG INJECTION:

• Manage
  advanced non-small cell lung cancer (NSCLC)
• Manage
  malignant pleural mesothelioma (cancer of the protective layer of the
  lungs)

How to use PEXOTRA 500MG INJECTION:

Your dose and frequency of administration will be decided by
your physician based on your disease condition and other factors. It will be
given to you by a healthcare professional. Do not self-administer.